Study of EDP167 for homozygous familial hypercholesterolemia
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests a new drug, EDP167, for people with homozygous familial hypercholesterolemia (HoFH), a genetic condition that causes very high cholesterol. The goal is to see if EDP167 can lower 'bad' cholesterol (LDL-C).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and weigh at least 40 kg.
- You have a genetic or clinical diagnosis of HoFH.
- Your fasting 'bad' cholesterol (LDL-C) is at least 2.6 mmol/L.
- You are on a stable, low-fat diet and lipid-lowering medications.
- You have not used certain investigational drugs or procedures (like apheresis) recently.
- You agree to use contraception if applicable and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, CTX310, for people with persistently high levels of fats (triglycerides) and cholesterol that have not improved with standard treatments. It aims to see if the drug is safe and tolerable.
This study tests a new injection called SYH2053 for people with HeFH, a genetic condition that causes very high cholesterol. It looks at whether the injection can safely lower LDL cholesterol when added to standard statin therapy.
This trial tests a new medicine called EDP167 for adults with mixed dyslipidemia, a condition of high cholesterol and triglycerides. It aims to see if the drug lowers lipids more than current treatments and how safe it is.
This study tests an investigational medicine called QLC7401 for people with a genetic condition called heterozygous familial hypercholesterolemia, which causes very high cholesterol. It aims to see if the new medicine can further lower bad cholesterol when added to your usual cholesterol treatments.
This study tests a new injectable medication (SYH2070) designed to lower cholesterol in people with homozygous familial hypercholesterolemia—a genetic condition that causes extremely high cholesterol levels despite treatment. The goal is to see if this drug safely reduces cholesterol better than current options.
This study tests a new injection called ART002g1 for people with an inherited form of high cholesterol (heterozygous familial hypercholesterolemia). The goal is to see if it is safe and can help lower cholesterol levels.
Hear when a new Homozygous Familial Hypercholesterolemia (HoFH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.